UNION CITY, Calif.--(BUSINESS WIRE)--Questcor Pharmaceuticals, Inc. (AMEX:QSC) provided today a progress report on the company’s new pricing strategy for H.P. Acthar Gel(R), a natural form of adrenocorticotropic hormone (ACTH). Since August 27, 2007, when the new strategy was announced, results have met Questcor’s expectations. Specifically, while overall units shipped have decreased, the company has seen an expansion of revenues, reflecting a positive pattern of ordering and insurance reimbursement at the new pricing level. In conjunction with the new strategy, Questcor has significantly expanded its sponsorship of Acthar patient assistance and co-pay assistance programs, which provide an important safety net for uninsured and under-insured patients using Acthar.
